MGMT and central nervous system cancer: Additionally, the Gliocan RUO kit is designed to sequence DNA sequence alterations in IDH1, IDH2, ATRX, BRAF, and TP53, along with detecting 1p/19q-codeletion and p-MGMT methylation (Central Nervous System Tumors, 2023).